News

December 06, 2010

D. Medical/Spring hires Chief Commercial Officer

D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMDC) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced the appointment of Zoe H. Myers as the Company's Chief Commercial Officer, effective February 1, 2011. Ms. Myers' responsibilities will include leading global commercial strategy and U.S. operations for D. Medical.

Ms. Myers is an international business leader with an accomplished history of opening new markets for novel diabetes devices. She joins D. Medical from her current position as Advisor at MC2 Consulting, Inc., a consulting firm that manages the full product lifecycle, including the development of business and marketing plans, for emerging R&D companies.

Ms. Myers, 45, began her professional career in the diabetes device space in 1994 as a Territory Manager for Disetronic AG, a world leader in the research and development of insulin pumps and injection systems. There, she progressed through a number of sales and operations management positions and, at the time of Roche Diagnostics Corporation's acquisition of Disetronic in 2003, was National Director of North American Field Operations, managing 110 employees responsible for sales, reimbursement and clinical services. Among many accomplishments while with Roche, Ms. Myers played a key role in securing Medicare reimbursement for insulin pump therapy. She served two terms in a volunteer position with American Association for Clinical Endocrinology ("AACE") as the Chair of the AACE Corporate Advisory Board in 2001-03, and is a past board member of the Lawson Wilkins Pediatric Endocrinology Society. Based on her success and reputation in the diabetes industry, Ms. Myers was recruited in 2005 to join Exsulin, Inc., developer of a peptide-based drug in Phase II clinical trials targeted at regeneration of insulin-producing islets in patients with established Type 1 Diabetes. Ms. Myers served as Exsulin's Vice President of Marketing and Strategic Communication until joining MC2 Consulting in 2009. Ms. Myers is a graduate of the School of Foreign Service at Georgetown University, with a Masters of Science from Johns Hopkins University.

"We are very pleased to have attracted a leader of Zoe Myers' caliber to this key position. Her extensive and demonstrable record of accomplishment in commercializing new diabetes treatments and insulin delivery devices will be a great asset for D. Medical going forward," commented Efri Argaman, D. Medical's Chief Executive Officer.

Zoe Myers said, "As D. Medical enters into the most exciting phase of a company's development, I see my new role as driving the three A's of any successful medical device roll out – Awareness, Acceptance and Adoption. I am confident that the Company's innovative technology portfolio, combined with the elegance of its design, will provide all the tools we need to accomplish our commercial goals and objectives."

Back